- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01246037
Beta-blockers in i-PAH
Beta-blocker Therapy in Idiopathic Pulmonary Arterial Hypertension
The main question of this study is: 'Is selective beta-blocker treatment safe and effective in reducing sympathetic overdrive, thereby improving RV function and remodeling in patients with iPAH?'.
In addition to the determination of RVEF, the investigators will explore how beta-blocker therapy affects sympathetic overdrive, remodeling of the RV, single beat elastance, exercise capacity and mechanical efficiency.
30 iPAH patients will be randomized to either Bisoprolol- or placebo-treatment in a double-blinded fashion. A cross-over trial design will be used to increase the power of the study and to assess long-term effects of Bisoprolol-treatment and -withdrawal. The medication will be given in an escalating dose regimen (as described in the 'farmacotherapeutisch kompas', www.fk.cvz.nl) and treatment will be monitored along the guidelines of the American Heart Association.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a clinical study aimed to provide a proof of concept of the safety and efficacy of beta-blocker treatment in PAH-associated right ventricular failure.
The protocol of the proposed double blinded cross over design.
The reasons for not choosing an initial open phase 1 study, but to start directly with a placebo controlled study are:
- Although the drug is considered contraindicated in the studied patient population, it is very common for PAH patients to receive beta-blocker therapy in an uncontrolled way; without reports of serious side effects until now
- Dose titration in the study will be performed on the basis of side-effects and at this moment the investigators cannot predict the optimal dose which is both safe and efficacious. Therefore, safety assessment can only be performed in combination with the assessment of pharmaceutical effectiveness.
After obtaining informed consent, 30 idiopathic PAH patients (NYHA II-III) will be randomly assigned to either the placebo group or beta-blocker therapy. For the randomization and study blinding the investigators will use a VUMC computer based procedure in close collaboration with the VUMC pharmacy.
In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' (described below) and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
MEASUREMENTS Time points 1, 3 and 5 (6 months periods): this includes a complete assessment of the patient
- Clinical assessment: physical examination, NYHA class, ECG, routine lab including NT-proBNP and urine tests for proteinuria.
- Imaging of right ventricular function: the primary measure of this study will be right ventricular ejection fraction measured by means of MRI. Additional MRI and echocardiographic measurements will be performed. (the complete study protocols are added as supplements).
- Right Heart Catheterization (performed under local anesthesia): Measurements of pressures in the pulmonary artery, right ventricle and right atrium, while patients are breathing room air and at end-expiration.
- Exercise capacity by means of a maximal incremental cycle testing (CardioPulmonary Exercise Test) to measure maximal work load, VO2 max, anaerobic threshold, heart rate response, oxygen pulse and ventilatory efficiency. And by means of 6 minute walking distance.
- Heart Rate Variability (HRV)
- Nuclear scanning: a comprised PET protocol will be performed to measure 11C-acetaat, oxygen-15-labeled water (H215O) and ¹¹C-HED uptake in the right ventricle. A summary of the protocol is added as a supplement.
UP-TITRATION PHASE (first 4 months; either on placebo or Bisoprolol): patients will be monitored every second week under supervision of an experienced pulmonologist, specialized in PAH, and a cardiologist, specialized in chronic heart failure during a visit to the outpatient clinic. If no contra-indications are found the dose will be increased to the next step.
The investigators will start with a dosage of 1,25 mg Bisoprolol once daily. Every two weeks dosage is increased by 1,25 mg, until maximum dosage of 10 mg once a day is reached, or as high as tolerated by the patient.
Increasing the dosage will be stopped, or if needed the dosage will be reduced, in case of:
- systolic systemic pressure < 90 mmHg
- clinical progression in heart failure
- clinically relevant bradycardia or <60b/min
- progression of complaints
- drop in 6 minute walk distance > 15% The titration procedure for the placebo will be the same as for titration of Bisoprolol. The dosage of the medication will be altered for maximal four months and after this the patients will use a stable dose for the rest of the six month period.
Every clinical visit will at least contain a clinical assessment, assessment of NYHA class, 6 minute walk distance, ECG and a Minnesota quality of life questionnaire. Every fourth week NT-proBNP, kidney- and liver functions will be assessed. In addition, the patient will be instructed to use a diary to record his/her symptoms and body weight.
STABLE PHASE: It is expected that up to 4 months are required to reach an acceptable dose of Bisoprolol. After this up-titration phase, the patient will be followed closely during the remaining part of the six month period, using a stable medication dose. The monitoring includes continuation of the diary, monthly visits to the outpatient clinic including the measurements as described in the up-titration phase and a telephone call every 4 weeks in between office visits.
CROSS OVER After six months new measurements will be done. Thereafter the medication will be tapered down in a two week period and than finally stopped. This will be done to prevent the patients for possible side effects (rebound tachycardia) of stopping their medication. The same tapering down procedure will be performed after the third set of measurements.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands
- VUMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Idiopathic PAH patients
Stable on PAH specific treatment defined
- No change in PAH specific treatment in the past 6 months
- No change in functional class in the past 6 months
- <10 % change in 6 minute walk distance in the past 6 months
- Functional class 2 or 3
- In sinus rhythm
Exclusion Criteria:
- History of systemic hypertension, ischaemic heart disease, valvular disease or cardiomyopathy.
- Asthma
- Use of concomitant medication other than diuretics, Acenocoumarol and PAH targeted therapy
- History of cardiac arrhythmias or the use of anti-arrhythmic drugs
- Sick sinus syndrome
- systolic hypotension < 90 mmHg
- AV-block
- Clinically relevant sinus-bradycardia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: First placebo
First half year placebo, second half year bisoprolol
|
In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines.
Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
|
Experimental: First Bisoprolol
First half year bisoprolol, second half year placebo
|
In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines.
Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectivity
Time Frame: 6 months
|
The primary efficacy endpoint is improvement in RV function as reflected by RVEF determined by means of cardiac MRI.
|
6 months
|
Safety
Time Frame: continue
|
Safety of Bisoprolol treatment in iPAH patients is not taken as a primary endpoint but seen as a precondition for this study and will be closely monitored.
Dose titration will be guided by possible side effects.
|
continue
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Is Bisoprolol treatment effective in reducing sympathetic overdrive?
Time Frame: 0,6,12 months
|
Herefore the investigators use a C11-Hed-, H2O15- and a C11-acetate- nuclear scan
|
0,6,12 months
|
Is Bisoprolol effective in reversing maladaptive remodeling of the right ventricular wall, and does Bisoprolol thereby improve the diastolic properties of the right ventricle?
Time Frame: 0,6 and 12 months
|
Pressure-Volume loops will be reconstructed from the combined right heart catheterization data and MRI measurements
|
0,6 and 12 months
|
Is Bisoprolol treatment effective in improving the perfusion and mechanical efficiency (oxygen consumption per joule) of the heart?
Time Frame: 0,6,12 months
|
Perfusion will be measured by using the H2O tracer.
Oxygen consumption of the right ventricle will be estimated from the uptake of the acetate tracer.
Right ventricular power output will be derived from the right heart catheterization data.
|
0,6,12 months
|
Is Bisoprolol effective in improving exercise capacity?
Time Frame: Every two weeks
|
This will be measured by means of the maximal oxygen uptake which is measured by means of the incremental cardiopulmonary exercise test and six minute walking distance.
|
Every two weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anton Vonk Noordegraaf, Prof. MD PhD, VU University Medical Center, pulmonary department
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Hypertension, Pulmonary
- Hypertension
- Pulmonary Arterial Hypertension
- Familial Primary Pulmonary Hypertension
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Bisoprolol
Other Study ID Numbers
- 2010-262
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Arterial Hypertension
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Amsterdam UMC, location VUmcRecruitingIdiopathic Pulmonary Arterial HypertensionNetherlands
Clinical Trials on Bisoprolol
-
Merck KGaA, Darmstadt, GermanyMerck Ltd.Completed
-
Merck KGaA, Darmstadt, GermanyMerck Gesellschaft mbH, AustriaCompleted
-
Merck KGaA, Darmstadt, GermanyCompletedHypertensionGermany
-
Université de SherbrookeLaval UniversityCompleted
-
State Institution "Republican Scientific and Practical...CompletedWomen With Breast CancerBelarus
-
Asan Medical CenterMerck Sharp & Dohme LLCTerminated
-
Merck KGaA, Darmstadt, GermanyMerck Inc., PhilippinesCompleted
-
Peking Union Medical College HospitalNational Natural Science Foundation of China; Cancer Institute and Hospital...Recruiting
-
Damanhour UniversityAlexandria UniversityCompletedAcute Coronary SyndromeEgypt
-
Damanhour UniversityAlexandria UniversityCompletedAcute Coronary SyndromeEgypt